Shireen, RBrennan, DFlannelly, GFennelly, DLenehan, PFoley, M2012-07-112012-07-112012-02Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. 2012, 105 (2):47-50 Ir Med J0332-310222455239http://hdl.handle.net/10147/233251Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.enArchived with thanks to Irish medical journalAdenocarcinomaAdenocarcinoma, MucinousChemotherapy, AdjuvantCystadenocarcinoma, SerousFemaleHumansNeoplasm, ResidualOvarian NeoplasmsPaclitaxelArticleIrish medical journal